Telomir Pharmaceuticals, Inc. · NASDAQ:TELO
Telomir Pharmaceuticals — Investor Presentation (February 2026)
70 slides from Telomir Pharmaceuticals's investor presentation, February 2026
Slide 1: Designed to reverse cellular aging...
Designed to reverse cellular aging... February 2026 Nasdaq: TELO
Slide 2: Corporate Overview
Corporate Overview Telomir Pharmaceuticals (Nasdaq: TELO) is a preclinical biotech company developing Telomir-1, a first-in-class small oral molecule designed to address T E L O M I R P H A R M A . C O M the fundamental biological drivers of aging and age-related disease. Our goal is to intervene at
Slide 3: Oral Small Molecule Targeting Core Drivers of Aging and Disease
Oral Small Molecule Targeting Core Drivers of Aging and Disease Telomir-1 restores cellular resilience by: Demonstrated preclinical activity across: T E L O M I R P H A R M A . C O M • Correcting toxic iron and copper • Retinal degeneration imbalance • Progeroid aging models • Supporting telomere st
Slide 4: Our Pipeline
Our Pipeline Indications Pre-Clinical Phase-I Phase-II Oncology T E L O M I R P H A R M A . C O M AMD Telomir-1 Type 2 diabetes Wilson’s disease Progeria 3 Investor Presentation | Nasdaq: TELO
Slide 5: Telomir Management
Telomir Management Erez Aminov | Chairman & CEO Itzchak Angel, PhD | Chief Scientific Advisor ▪ A biotechnology leader driving innovation in drug ▪ Over 40 years of experience in guiding medical, development and strategic growth. pharmaceutical, drug, and business development in both large and emerg
Slide 6: Telomir Advisors
Telomir Advisors Francis E. O’Donnell, Jr., M.D. | Special Advisor Michael Roizen, M.D. | Special Advisor ▪ Dr. O’Donnell leads clinical strategy and evaluates ▪ Dr. Michael Roizen, an advisor to the Company since 2023, is potential products for unmet medical needs. Chief Wellness Officer Emeritus a
Slide 7: Therapeutic Areas
Therapeutic Areas Key ongoing initiatives include: Cancer Models Exploring epigenetic mechanisms and anti- cancer applications using in vitro and xenograft studies. Alzheimer’s Disease, Spasmodic Dysphonia Wilson’s Disease Study T E L O M I R P H A R M A . C O M and other neuronal and muscle disease
Slide 8: Impact of Iron Overload
Cellular Impact of Iron Overload ▪ Oxidative stress ▪ Mitochondrial dysfunction ▪ DNA dysfunction Iron Overload ▪ Epigenetics ▪ Ferroptosis ▪ Cellular senescence T E L O M I R P H A R M A . C O M Functional ▪ Cancer ▪ Accelerated aging Pathology ▪ Senescence ▪ Cancer ▪ Telomer shortening ▪ Progeria
Slide 9: Impact of Iron and Copper Overload
Impact of Iron and Copper Overload Iro n Ove rloa d Copp er Ove rlo ad Cancer T E L O M I R P H A R M A . C O M Accelerated Aging Cancer Wilson’s Disease Alzheimer’s Disease Metabolic Syndrome Menkes Disease AMD Fredrick’s Ataxia AMD Hemochromatosis 8 Investor Presentation | Nasdaq: TELO
Slide 10: Mechanism of Action
Mechanism of Action Telomir-Zn enters the cell, captures excess iron or copper, and swaps them for protective zinc — removing toxic metals and restoring healthy cellular balance. T E L O M I R P H A R M A . C O M In the Cell + Outside the Cell 9 Investor Presentation | Nasdaq: TELO
Slide 11: Telomir-1 can effectively bind and modulate several ions
Telomir-1 can effectively bind and modulate several ions. It has high affinity for iron and copper and lower affinity for zinc. T E L O M I R P H A R M A . C O M White: Hydrogen Blue: Nitrogen Gray: Carbon Orange: Metal 10 Investor Presentation | Nasdaq: TELO
Slide 12: Telomir-1 has high affinity for iron and copper and lower affinity for zinc
Telomir-1 has high affinity for iron and copper and lower affinity for zinc. T E L O M I R P H A R M A . C O M Copper Replaces Bound Iron to Telomir-1 Zinc Does Not Replace Bound Iron to Telomir-1 11 Investor Presentation | Nasdaq: TELO
Slide 13: Mechanism of Action
Mechanism of Action Direct measurements in HaCat cells of the effects of Telomir-1 on intracellular iron, as stained with FerroOrange at 24 hours: T E L O M I R P H A R M A . C O M High Intracellular Iron (Yellow Color) Reduced Intracellular Iron (Yellow Color) Relative Relative Intensity Intensity
Slide 14: Telomir-1 achieves greater intracellular iron reduction than DFO at 6 hours
Telomir-1 achieves greater intracellular iron reduction than DFO at the 6- hour mark, even though DFO is the stronger chelator in vitro. T E L O M I R P H A R M A . C O M Incubation time :6 hours 13 Investor Presentation | Nasdaq: TELO
Slide 15: Telomir-1 outperforms DFO in lowering intracellular iron at 3 hours
Telomir-1 outperforms DFO in lowering intracellular iron at the 3-hour mark. T E L O M I R P H A R M A . C O M 14 Investor Presentation | Nasdaq: TELO
Slide 16: Telomir-Zn induces an exchange between intracellular iron and zinc
Telomir-Zn induces an exchange between intracellular iron and zinc Enhanced Intracellular Zinc Levels Reduced Intracellular Iron Levels 15 Investor Presentation | Nasdaq: TELO
Slide 17: Mechanism of Action
Mechanism of Action Telomir-Zn enters the cell, captures excess iron or copper, and swaps them for protective zinc — removing toxic metals and restoring healthy cellular balance. T E L O M I R P H A R M A . C O M In the Cell + Outside the Cell 16 Investor Presentation | Nasdaq: TELO
Slide 18: Aging and Longevity Research
Aging and Longevity Research • Telomeres • Lifespan and healthspan T E L O M I R P H A R M A . C O M • Mechanisms of action 17 Investor Presentation | Nasdaq: TELO
Slide 19: What are Telomeres?
What are Telomeres? Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins (TTAGGG). Female Male T E L O M I R P H A R M A . C O M XX XY ▪ Telomeres protect chromosome ends during cell division, preventing gene loss, like Genetic shoelace caps. Material ▪ This co
Slide 20: Telomir-1 Restores Telomere Length in Accelerated Aging Models
Telomir-1 Restores Telomere Length in Accelerated Aging Models Study Model & Design: • Zebrafish model exhibiting rapid telomere loss and aging, mimicking biology of both Progeria T E L O M I R P H A R M A . C O M and Werner syndromes • Dosing: Oral Telomir-1 for 14 days Key Results: • Untreated fis
Slide 21: Telomir-1 significantly extended nematode lifespan
Telomir-1 significantly extended nematode lifespan, demonstrating a strong longevity effect. Study Overview: This study measured Telomir-1’s impact on T E L O M I R P H A R M A . C O M lifespan, healthspan, and mobility in real time. Key Findings Included: Increased Lifespan: Enhanced Motility: Redu
Slide 22: Study in Adult Progeria (Accelerated Aging Disease)
Study in Adult Progeria (Accelerated Aging Disease) The study used C. elegans with a wrn-1 gene mutation, the human equivalent of which is linked to Werner Syndrome (Adult Progeria), showing reduced life expectancy compared to wild-type nematodes. T E L O M I R P H A R M A . C O M Key Findings Inclu
Slide 23: Telomir-1 normalizes reduced viability induced by copper and iron in progeria cells
Telomir-1 normalizes reduced viability induced by copper and iron in progeria cells Study Summary: • Progeria fibroblasts were treated with increasing concentrations of Telomir-1 following exposure to copper (Cu) and iron (Fe). 0.80 Conc Telomir T E L O M I R P H A R M A . C O M • Viability/metaboli
Slide 24: Reduces ROS and Reverses Oxidative Stress Induced by Copper and Iron
Telomir-1 Reduces ROS and Reverses Oxidative Stress Induced by Copper and Iron Study Summary: • Progeria fibroblasts were evaluated for reactive oxygen species (ROS) levels 24 hours after treatment with varying concentrations of Telomir-1. 400,000 Conc T E L O M I R P H A R M A . C O M Telomir • Cel
Slide 25: Telomir-1 Protects Progeria Cells from Multiple Mitochondrial Stressors
Telomir-1 Protects Progeria Cells from Multiple Mitochondrial Stressors Study Summary: • Measured ROS, calcium, and viability in progeria 1.5 fibroblasts under copper/iron-induced stress. 0 T E L O M I R P H A R M A . C O M 1.4 0.3 Key Results: 1.3 1.1 • Copper/iron increased ROS and calcium; 3.3 Re
Slide 26: Telomir-1 Activates Mitochondrial Activity in Progeria Cells
Telomir-1 Activates Mitochondrial Activity in Progeria Cells Dose-dependent normalization of intracellular calcium linked to mitochondrial protection Study Summary: Progeria cells • Assessed mitochondrial activity and proliferation in T E L O M I R P H A R M A . C O M progeria fibroblasts. Key Resul
Slide 27: Telomir-1 Activates Mitochondrial Activity in Progeria Cells
Telomir-1 Activates Mitochondrial Activity in Progeria Cells Dose-dependent normalization of intracellular calcium Augmentation of Mitochondrial Activity linked to mitochondrial protection Study Summary: • We studied the effects of Telomir-1 on Progeria fibroblasts, evaluating key parameters mitocho
Slide 28: Cancer Research
Cancer Research • Anti-cancer activity T E L O M I R P H A R M A . C O M • Epigenetics • Mechanisms of action 27 Investor Presentation | Nasdaq: TELO
Slide 29: Pre-Clinical Research
Pre-Clinical Research Viability on Different Cell Types Significant anti-cancer activity in different cancer cell Cell Cancer Iron IC50 types Type Dependency (µM) Telomir-1 kills different cancer cell types with variable potency MDA MB TNBC Highest 0.54 231 T E L O M I R P H A R M A . C O M Results:
Slide 30: Significant Anti-Cancer Activity in BT 549 Breast Cancer Model
Significant Anti-Cancer Activity in BT 549 Breast Cancer Model Key Study Highlights: Model Used: • Human triple negative breast cancer BT549 cells T E L O M I R P H A R M A . C O M in zebrafish xenograft model • Telomir-1 was administered orally daily for 3 days to zebra fish embryos implanted with
Slide 31: Significant Anti-Cancer Activity in BT 549 Breast Cancer Model
Significant Anti-Cancer Activity in BT 549 Breast Cancer Model Key Study Highlights: Model Used: • Human triple negative breast cancer BT549 cells in T E L O M I R P H A R M A . C O M zebrafish xenograft model • Telomir-1 was administered orally daily for 3 days to zebra fish embryos implanted with
Slide 32: Significant Anti-Cancer Activity in Chemotherapy Resistant HCC1806 Breast Cancer Model
Significant Anti-Cancer Activity in Chemotherapy Resistant HCC1806 Breast Cancer Model Key Study Highlights: Model Used: • Human triple negative chemotherapy resistant breast cancer T E L O M I R P H A R M A . C O M HCC1806 cells, in zebrafish xenograft model • Telomir-1 was administered orally dail
Slide 33: Pre-Clinical Research
Pre-Clinical Research Significant anti-cancer activity in prostate cancer Telomir-1 Does Not Change Telomer Size in Cancer model Telomir-1 does not modify telomer length in Aggressive Human Prostate Cancer Model T E L O M I R P H A R M A . C O M Key Study Highlights: • Telomere length determined by
Slide 34: Promising Efficacy in Aggressive Human Prostate Cancer Model
Promising Efficacy in Aggressive Human Prostate Cancer Model Key Study Highlights: Model Used: human prostate cancer PC3 cells T E L O M I R P H A R M A . C O M Results: • Telomir-1 significantly inhibited tumor growth Significance: • Suggests Telomir-1 may hold potential as a novel therapeutic cand
Slide 35: Significant Anti-Cancer Activity in Prostate Cancer Model
Significant Anti-Cancer Activity in Prostate Cancer Model Key Study Highlights: Model Used: • Human prostate cancer PC3 cells in mice xenograft T E L O M I R P H A R M A . C O M model • Telomir-1 was administered orally daily for 21 days to mice implanted with PC3 cells Results: • Telomir-1 showed t
Slide 36: Restoring Tumor-Suppressor Genes Through Epigenetic Regulation
Restoring Tumor-Suppressor Genes Through Epigenetic Regulation Key Highlights: • Prostate cancer progression is driven by abnormal DNA methylation that silences key tumor- suppressor genes (e.g., GSTP1, CDKN2A, T E L O M I R P H A R M A . C O M RASSF1A, MASPIN). • Study used a PC3 human prostate can
Slide 37: Telomir-1 Reduces Stat-1 DNA Methylation
Telomir-1 Reduces Stat-1 DNA Methylation – Critical Immune-Signaling Gene Key Study Highlights: • STAT1 is a key tumor-suppressor pathway that drives interferon-mediated immune surveillance. • Excess iron and copper can disrupt JAK/STAT signaling and T E L O M I R P H A R M A . C O M suppress STAT1
Slide 38: Telomir-1 Reduces CDKN2A DNA Methylation
Telomir-1 Reduces CDKN2A DNA Methylation – a Major Tumor-Suppressor Gene Key Study Highlights: • CDKN2A is a major tumor-suppressor gene regulating cell-cycle control; its promoter is hypermethylated in ~30–50% of prostate cancers, especially aggressive types. T E L O M I R P H A R M A . C O M Resul
Slide 39: Telomir-1 Reduces TMS1 DNA Methylation
Telomir-1 Reduces TMS1 DNA Methylation – Key Cell-Death Regulator Frequently Silenced in Cancer Key Study Highlights: • TMS1 (ASC) is a tumor-suppressor gene often silenced by DNA methylation in 24–40% of breast cancers; not methylated in normal T E L O M I R P H A R M A . C O M tissue. • Its silenc
Slide 40: Telomir-1 Reduces GSTP1 DNA Methylation
Telomir-1 Reduces GSTP1 DNA Methylation - a Critical DNA-Protection and Detoxification Gene Key Study Highlights: • GSTP1 is a major detoxification and DNA-protection enzyme. T E L O M I R P H A R M A . C O M • It is hypermethylated and silenced in >90% of prostate cancers, leading to excess ROS, DN
Slide 41: Telomir-1 Demonstrates Reduction of RASSF1A Hypermethylation
Telomir-1 Demonstrates Reduction of RASSF1A Hypermethylation – a Gene Linked to Uncontrolled Cell Growth Key Study Highlights: • RASSF1A is a key tumor-suppressor gene controlling microtubule stability, cell-cycle arrest, and apoptosis. T E L O M I R P H A R M A . C O M • It is frequently hypermethy
Slide 42: Telomir-1 Reduces MASPIN DNA Methylation
Telomir-1 Reduces MASPIN DNA Methylation a Gene That Prevents Invasion and Metastasis Key Study Highlights: • MASPIN is a tumor-suppressor often silenced by hypermethylation T E L O M I R P H A R M A . C O M in aggressive prostate cancer. • Loss of MASPIN promotes invasion and metastasis. Results: •
Slide 43: Telomir-1 Reduces CASP8 DNA Methylation
Telomir-1 Reduces CASP8 DNA Methylation - an Essential Enzyme that Initiates Cancer-Cell Death Key Study Highlights: • CASP8 is a key apoptosis-initiating gene often suppressed in cancer. T E L O M I R P H A R M A . C O M • Iron and copper stress may further inhibit its activity. Results: • High-dos
Slide 44: Exploring the Role of KDMs in Controlling Gene Activity
Exploring the Role of KDMs in Controlling Gene Activity Key Highlights: • KDMs regulate gene activity by removing methyl groups from histones. T E L O M I R P H A R M A . C O M • Dysregulated KDMs alter oncogene and tumor- suppressor control. • These enzymes require iron, linking them to cellular re
Slide 45: Telomir-1 Potently Inhibits Histone Demethylases KDM2 and KDM6
Telomir-1 Potently Inhibits Histone Demethylases (KDMs) - KDM2 and KDM6 Key epigenetic enzymes driving cancer growth, inflammation, and aging. Key Study Highlights: • FBXL10 (KDM2B) / FBXL11 (KDM2A): Cancer-driving enzymes that support tumor growth, stem-like behavior, and immune evasion T E L O M I
Slide 46: Telomir-1 Potently Inhibits Histone Demethylases (KDM5s, JARID1)
Telomir-1 Potently Inhibits Histon Demethylases 5 (KDM5s, JARID1) Key Study Highlights: • JARID1A (KDM5A): Epigenetic eraser that shuts down tumor- suppressor genes by removing activation marks. T E L O M I R P H A R M A . C O M • JARID1B (KDM5B): Drives cancer stem-cell survival by stripping activa
Slide 47: Telomir-1 Only Mildly Inhibits Tankyrases (PARP5)
Telomir-1 Only Mildly Inhibits Tankyrases (PARP5) Tankyrases regulate the Wnt/β-catenin growth pathway that many cancers rely on for uncontrolled proliferation. Key Study Highlights: • Telomir-1 shows low-level inhibition of Tankyrases (PARP5A/B), key regulators of the Wnt/β-catenin growth T E L O M
Slide 48: Telomir-1 Shows Minimal Interaction With mTOR and Toxicity-Linked Enzymes
Telomir-1 Shows Minimal Interaction With mTOR and No Activity on Key Toxicity-Linked Enzymes Key Study Highlights: • Telomir-1 shows very low affinity for mTOR (IC₅₀ ≈ 72 μM). T E L O M I R P H A R M A . C O M • No activity against GCN5L2 (KAT2A), a toxicity-linked acetyltransferase. • No interactio
Slide 49: Telomir-1 Has No Activity on Keap1-Nrf2
Telomir-1 Has No Agonist or Antagonist Activities on Keap1-Nrf2 – Maintaining a Clean Safety Profile with No Off-Target Effects Key Study Highlights: • Telomir-1 shows no agonist or antagonist activity on the Keap1- Nrf2 pathway. T E L O M I R P H A R M A . C O M • Keap1-Nrf2 is the body’s central o
Slide 50: Multifactorial Interaction of DNA-methylation, KDMs and Tankyrases
Multifactorial Interaction of DNA-methylation, KDMs and Tankyrases on Key Processes GSTP1 CASP8 CANCER AGING RASSF1A MASPIN • Epigenetic drift • Oncogenic • Tumor promoting • Activation of senescence STAT1 CDKN2A genes T E L O M I R P H A R M A . C O M • Tumor plasticity • Immune evasion • Accelerat
Slide 51: Pre-Clinical Research: Additional Potential Indications
Pre-Clinical Research Additional Potential Indications T E L O M I R P H A R M A . C O M • Type two diabetes • Age-related macular degeneration (AMD) • Wilson’s disease • Progeria and Werner’s syndrome Investor Presentation | Nasdaq: TELO 50
Slide 52: Reversal of Key Type 2 Diabetes Parameters
Reversal of Key Type 2 Diabetes Parameters Study Overview and Results: Telomir-1 was tested in a high-fat–diet Type 2 diabetes Zebrafish model, evaluating fasting glucose, insulin levels, glucose tolerance (OGTT), and insulin resistance (HOMA-IR). T E L O M I R P H A R M A . C O M Key Findings Inclu
Slide 53: Telomir-1 Protects Retinal Cells from Copper-Induced Oxidative Stress
Telomir-1 Protects Retinal Cells from Copper-Induced Oxidative Stress Study Overview: ARPE-19 retinal cells exposed to excess copper; Telomir-1 tested across doses and ROS measured. T E L O M I R P H A R M A . C O M Key Findings: • Telomir-1 lowers baseline oxidative stress. • Copper sharply increas
Slide 54: Telomir-1 Protects Retinal Cells from Copper- and Iron-Induced Calcium
Telomir-1 Protects Retinal Cells from Copper- and Iron-Induced Calcium Study Overview: ARPE-19 retinal cells exposed to copper; intracellular calcium measured across Telomir-1 doses. T E L O M I R P H A R M A . C O M Key Findings: • Copper triggers a sharp calcium surge linked to mitochondrial damag
Slide 55: Telomir-1 Restores Vision, Retinal Structure in AMD Zebrafish Model
Telomir-1 Restores Vision, Retinal Structure, and Reduces Oxidative Damage in AMD Zebrafish Model In a dry AMD model, Telomir-1 achieved functional vision recovery and structural regeneration—marking the first oral regenerative candidate. T E L O M I R P H A R M A . C O M • Restored central vision:
Slide 56: Telomir-1 Restores Vision in AMD Model
Telomir-1 Restores Vision in AMD Model Varying Light Response First Oral Therapy Showing Regenerative Effects in FDA- Surrogate AMD Model Study Overview: • Model: 18-month-old Sen57wrn⁻/⁻ND6⁻/⁺ zebrafish — recapitulates dry AMD with central vision loss, retinal thinning, oxidative stress and ~15% mo
Slide 57: Telomir-1 Rebuilds Retinal Layers in AMD Model
Telomir-1 Rebuilds Retinal Layers in AMD Model Whole Retinal Layers Telomir-1 Restores Vision & Retinal Structure in AMD Model First Oral Therapeutic Showing Regenerative Effects in FDA- Surrogate-Driven Proof-of-Concept T E L O M I R P H A R M A . C O M Structural Regeneration • Full restoration of
Slide 58: Telomir-1 Rebuilds Retinal Layers in AMD Model
Telomir-1 Rebuilds Retinal Layers in AMD Model Percent Retinal Degeneration Telomir-1 Restores Vision & Retinal Structure in AMD Model First Oral Therapeutic Showing Regenerative Effects in FDA- Surrogate-Driven Proof-of-Concept Structural Regeneration: T E L O M I R P H A R M A . C O M • Marked imp
Slide 59: Telomir-1 Reverses Key Aging Markers in Werner Syndrome Model
Telomir-1 Reverses Key Aging Markers in Werner Syndrome Model Telomere length and DNA methylation patterns were normalized in Sen57wrn⁻/⁻ zebrafish—exceeding wild-type levels at higher doses. T E L O M I R P H A R M A . C O M • Mutant zebrafish showed severe telomere shortening characteristic of Wer
Slide 60: Telomir-1 Restores Physical and Cellular Health in Werner Syndrome Model
Restoration of Lost Muscle Weight Telomir-1 Restores Physical and Cellular Health in Werner Syndrome Model 14-day oral treatment reverses muscle loss and oxidative stress in Sen57wrn⁻/⁻ zebrafish • Mutant fish displayed significant loss of body and T E L O M I R P H A R M A . C O M muscle mass • Tel
Slide 61: Telomir-1 Achieves Full Survival and Broad Rejuvenation in Werner Syndrome Model
Telomir-1 Achieves Full Survival and Broad Rejuvenation in Werner Syndrome Model 14-day treatment in Sen57wrn⁻/⁻ zebrafish reverses aging hallmarks and eliminates mortality Study Model & Results: Survival Analysis – no animals died when treated with telomir-1 Sen57wrn⁻/⁻ND6⁻/⁺ zebrafish recapitulati
Slide 62: Telomir-1 Restores Neuromotor Function in Wilson's Disease Model
Telomir-1 Restores Neuromotor Function and Reverses Organ Dysfunction in Wilson’s Disease Model Dose-Dependent Reversal of Neurological, Hepatic & Renal Damage in Episodic Tremor Events ATP7B⁻/⁻ Zebrafish Study Overview: • Model: ATP7B C271X⁻/⁻ zebrafish, replicating human Wilson’s disease pathology
Slide 63: Telomir-1 Reverses Multi-Organ Dysfunction in Wilson's Disease Model
Telomir-1 Reverses Multi-Organ Dysfunction in Wilson’s Disease Model Liver Copper Levels Dose-Dependent Reversal of Neurological, Hepatic & Renal Damage in ATP7B⁻/⁻ Zebrafish Hepatic & Renal Benefit: • ~50% reduction in liver copper accumulation T E L O M I R P H A R M A . C O M • Histopathology sco
Slide 64: Pre-clinical Research Summary
Pre-clinical Research Summary Domain Main characteristics details Pharmacology Selective metal ion chelator Fe>Cu>>Zn • Telomir-1 is rapidly absorbed in rat and dog with rapid elimination half-life T E L O M I R P H A R M A . C O M ADME Absorption • Was stable in mouse, rat, dog, monkey, and human p
Slide 65: Anticipated Timeline for TELOMIR-1
Anticipated Timeline for TELOMIR-1 T E L O M I R P H A R M A . C O M 2 0 25 2 0 25 2 0 25 2 0 26 Q2 Q3 Q4 Q1 ▪ CMC (Chemistry, ▪ GMP CMC (Chemistry, ▪GMP CMC (Chemistry, ▪Toxicology: Completion Formal Manufacturing, and Manufacturing, and Manufacturing, and Controls): Toxicology Controls): Stability
Slide 66: Market Opportunity
Market Opportunity Summary of USEpidemiology The eligible patient pool analysisfor Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Diagnosed Total Addressable Population Treatment Rate Prevalen
Slide 67: Market Opportunity for Rare Diseases
Market Opportunity for Rare Diseases Summary of US Epidemiology The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Total Diagnosed Population Treatment Rate
Slide 68: Growth Strategy
Growth Strategy Continue pre-clinical development of Telomir-1 across a range of diseases and progress into T E L O M I R P H A R M A . C O M clinical development Advance Telomir-1 through clinical development and FDA approval Identify additional product candidates and expand current candidates into
Slide 69: Investment Highlights
Investment Highlights Telomir-1 T E L O M I R P H A R M A . C O M TELOMIR-1 is novel small Based on our pre-clinical The Company’s goal is to molecule metal ion studies to date we explore the potential of regulator, with a broad assemble experimental Telomir-1 starting with potential to affect sever
Slide 70: Thank you.
Thank you. 100 SE 2nd Street Suite 2000 #1009 Miami, FL 33131 TelomirPharma.com
Telomir Pharmaceuticals — Investor Presentation (February 2026) on 6ix